There are drug-drug interactions between the COVID-19 treatment ritonavir/nirmatrelvir and various classes of commonly used CV medications, according to a review paper.
The review document, published in the Journal of the American College of Cardiology, provides an overview of the contraindications of ritonavir/nirmatrelvir (Paxlovid, Pfizer) across common antiplatelets/anticoagulants, lipid-lowering agents, antianginal drugs, antihypertensive agents, antiarrhythmic drugs, HF therapies, pulmonary hypertension therapies, immunosuppressive agents and anti-inflammatory drugs.
“Patients with